Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Cytarabine and UCN-01 in Treating Patients With Refractory or Relapsed Acute Myelogenous Leukemia or Myelodysplastic Syndrome

This study has been completed.
National Cancer Institute (NCI)
Information provided by (Responsible Party):
M.D. Anderson Cancer Center Identifier:
First received: January 28, 2000
Last updated: July 27, 2012
Last verified: July 2012
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: January 2007
  Primary Completion Date: January 2007 (Final data collection date for primary outcome measure)